Adarza Aims to Launch Biomarker Detection Platform Next Year; Adds Former Roche CEO to Board

The company disclosed two additions to its board of directors, including former Roche Molecular Systems CEO Heiner Dreismann, as it moves to commercialize its AIR biomarker detection platform for clinical research and diagnostic applications.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.